RxDoctor Payments Data

Rodney Ellis, MD

Internal Medicine · Lanham, MDNPI 1104986405

Payments from drug & device makers

$10,561in general payments, 2019–2025

Across 529 payments — averaging $19.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AstraZeneca$1K
  • Amgen$938
  • Vanda Pharmaceuticals Inc.$866
  • Lilly USA, LLC$739
  • Bayer$470
  • plus $4K from 38 others

What the payments were for

  • Food & beverage$10,49099%
  • Education$711%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,561 in reported general payments places this provider in the 90th percentile of 2,979 internal medicine providers in Maryland.

See all internal medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$120,911
Medicare patients
324
Services billed
1,474

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ImbruvicaIbrutinib11$179,190
OzempicSemaglutide43$74,008
RybelsusSemaglutide24$42,972
EliquisApixaban31$36,071
JanuviaSitagliptin Phosphate21$24,607
FarxigaDapagliflozin Propanediol24$23,369
MounjaroTirzepatide14$18,870
Janumet XrSitagliptin Phos/Metformin Hcl17$16,499
Soliqua 100-33Insulin Glargine/Lixisenatide19$16,423
JardianceEmpagliflozin12$11,298
Candesartan-HydrochlorothiazidCandesartan/Hydrochlorothiazid29$4,771
Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide66$4,695
Candesartan Cilexetil51$3,893
Atorvastatin Calcium344$3,747
Humalog Kwikpen U-100Insulin Lispro14$3,594

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$2,379$116,98067 claims
MerckJanuvia, Janumet Xr$171$41,10638 claims
PfizerEliquis$143$36,07131 claims
AstraZenecaFarxiga$1,310$23,36924 claims
Lilly USA, LLCMounjaro$739$18,87014 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$468$16,42319 claims
Boehringer IngelheimJardiance$318$11,29812 claims
Teva Pharmaceuticals USA, Inc.Qvar Redihaler$84$3,50617 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,979 internal medicine providers in Maryland.

Other internal medicine in Lanham

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →